Development of Hardware and Software for Pulmonary Magnetic Resonance Imaging Using Inhaled Tracer Gases
NCT ID: NCT04726618
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
24 participants
OBSERVATIONAL
2022-03-01
2024-04-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Design and Evaluation of Mobile X-ray for Rapid and Accurate Diagnosis of Thoracic Disease
NCT02391896
Comparative Evaluation of MRI and MDCT for the Detection of Metastic Pulmonary Nodules
NCT00751920
Advanced Imaging for Pulmonary Fibrosis
NCT06532071
Tracking Peripheral Blood Mononuclear Cells With Fluorine MRI
NCT02921373
Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration
NCT02316379
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conventional Magnetic Resonance Imaging (MRI) images the 1H nucleus (proton) attached to water molecules in biological tissues. MRI can provide high-resolution anatomical and functional information of the lung with multiparametric contrast without the use of ionizing radiation. However, major drawbacks associated with conventional 1H MRI of the lung are the low tissue density, large magnetic susceptibility differences between numerous air/tissue interfaces, and image corruption by cardiorespiratory motion during the necessarily long image acquisition time frame. Wo;;
One strategy which may be employed to overcome the limitations associated with conventional 1H MRI is the application of safe MR-sensitive inhaled tracer gases. This allows for the direct visualization of the spatial distribution of these gases, revealing regional ventilation directly. In this study we aim to develop, implement, and test these technologies for improved in-vivo imaging of lung structure and function in adults and children with no history of respiratory disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hyperpolarized 129-xenon gas and Perfluoropropane gas
Hyperpolarized 129-xenon gas will be used as a contrast agent for MRI. Xenon will be inhaled by the participant at a maximum dose volume of 1/6 of the participant's total lung capacity.
Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 6-75 years old
* In good general health as evidenced by medical history
* Meets MRI screening criteria
Exclusion Criteria
* FEV1 \<70%
* Requires supplemental oxygen
* Has had a respiratory infection within the past 2 weeks
* Pregnant or lactating\*
6 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Hospital for Sick Children
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giles Santyr
Senior Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giles Santyr, PhD
Role: PRINCIPAL_INVESTIGATOR
The Hospital for Sick Children
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital for Sick Children
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1000070140
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.